Detected ·
Aura Biosciences
——
Aura Biosciences (NASDAQ: AURA) closed an underwritten public offering of approximately $299.4 million gross proceeds to advance its precision therapies for solid tumors, with lead candidate bel-sar in late-stage development for early choroidal melanoma.
- Website
- www.aurabiosciences.com
- Amount
- —
- Stage
- —
- Event
- Funding round
- Detected
- 2026-05-07 20:14:05 UTC
- Signal ID
- 4f2f983b-1cf3-4e77-a338-f8682c567d82
As the API returns it
{
"id": "4f2f983b-1cf3-4e77-a338-f8682c567d82",
"created_at": "2026-05-07T20:14:05.455367Z",
"company_name": "Aura Biosciences",
"company_website_url": "www.aurabiosciences.com",
"company_linkedin_url": "https://www.linkedin.com/company/aurabiosciences",
"event_type": "funding",
"funding_amount": null,
"funding_currency": null,
"funding_stage": null,
"message": "*Aura Biosciences (NASDAQ: AURA) closed an underwritten public offering of approximately $299.4 million gross proceeds to advance its precision therapies for solid tumors, with lead candidate bel-sar in late-stage development for early choroidal melanoma.*"
}